Want to see HK:1302 full AI Analyst Report?
Top Page
LifeTech Scientific Corporation
(1302)
Select Model
Select Model
Rating:59Neutral
Price Target:
HK$1.50
▼(-5.06% Downside)
Action:Reiterated
Date:08/27/26
The score is primarily supported by strong recent revenue growth and a very conservative balance sheet, which lowers financial risk. Offsetting this are meaningful margin/ROE deterioration and a relatively high P/E valuation, while technical signals remain weak-to-neutral with the stock below longer-term moving averages.
Positive Factors
Revenue Growth
The sharp 2025 revenue re-acceleration indicates stronger demand and improving commercial traction across the company’s medical-device portfolio. If sustained, this growth can expand market presence, support operating investment, and provide a broader base for future earnings despite current profitability pressure.
Negative Factors
Margin Compression
The sustained decline in net margin shows that strong revenue growth is not translating proportionally into earnings. Continued compression could limit operating leverage, reduce the cash available for reinvestment, and make future results more dependent on maintaining unusually high sales growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The sharp 2025 revenue re-acceleration indicates stronger demand and improving commercial traction across the company’s medical-device portfolio. If sustained, this growth can expand market presence, support operating investment, and provide a broader base for future earnings despite current profitability pressure.
Read all positive factors
LifeTech Scientific Corporation (1302) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$6.69B
Dividend YieldN/A
Average Volume (3M)20.06M
Price to Earnings (P/E)103.6
Beta (1Y)0.66
Revenue Growth0.75%
EPS Growth-20.22%
CountryHK
Employees1,245
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.01
Shares Outstanding4,631,712,400
10 Day Avg. Volume23,911,510
30 Day Avg. Volume20,064,436
Financial Highlights & Ratios
PEG Ratio-1.21
Price to Book (P/B)1.76
Price to Sales (P/S)4.52
P/FCF Ratio12.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)HK$1.47B
LifeTech Scientific Corporation Business Overview & Revenue Model
Company Description
LifeTech Scientific Corporation, an investment holding company, develops, manufactures, and trades in interventional medical devices for cardiovascular and peripheral vascular diseases and disorders in Mainland China, Europe, Rest of Asia, India, ...
LifeTech Scientific Corporation Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
86
Very Positive
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.29B | 1.37B | 1.30B | 1.27B | 1.10B | 925.33M |
| Gross Profit | 987.25M | 1.02B | 981.43M | 995.64M | 873.93M | 747.53M |
| EBITDA | 277.17M | 266.10M | 296.37M | 253.46M | 445.78M | 397.59M |
| Net Income | 58.41M | 147.83M | 222.39M | 263.24M | 325.34M | 292.47M |
Balance Sheet | ||||||
| Total Assets | 4.75B | 5.01B | 4.90B | 4.70B | 3.69B | 3.18B |
| Cash, Cash Equivalents and Short-Term Investments | 1.24B | 1.20B | 1.18B | 1.18B | 833.79M | 1.48B |
| Total Debt | 14.10M | 8.04M | 4.98M | 9.30M | 9.67M | 15.67M |
| Total Liabilities | 1.48B | 1.48B | 1.42B | 1.37B | 769.05M | 653.61M |
| Stockholders Equity | 3.32B | 3.51B | 3.49B | 3.37B | 2.90B | 2.50B |
Cash Flow | ||||||
| Free Cash Flow | 480.76M | 501.49M | 38.46M | 125.36M | 52.84M | 145.57M |
| Operating Cash Flow | 531.28M | 555.01M | 321.46M | 418.05M | 388.32M | 488.85M |
| Investing Cash Flow | 353.57M | -73.91M | -517.53M | -453.88M | -458.47M | -86.76M |
| Financing Cash Flow | -666.93M | -383.59M | -116.97M | 182.71M | -215.20M | -256.38M |
LifeTech Scientific Corporation Technical Analysis
Positive
1.58
Price Trends
1.39
Positive
1.42
Positive
1.61
Negative
Market Momentum
0.05
Negative
59.87
Neutral
74.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1302, the sentiment is Positive. The current price of 1.58 is above the 20-day moving average (MA) of 1.44, above the 50-day MA of 1.39, and below the 200-day MA of 1.61, indicating a neutral trend. The MACD of 0.05 indicates Negative momentum. The RSI at 59.87 is Neutral, neither overbought nor oversold. The STOCH value of 74.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1302.
LifeTech Scientific Corporation Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.98B | 11.21 | 13.24% | 2.63% | 16.15% | 31.89% | |
67 Neutral | HK$4.71B | 21.32 | 10.38% | 1.74% | 3.83% | -27.04% | |
59 Neutral | HK$6.69B | 103.62 | 1.71% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
48 Neutral | HK$2.65B | -15.75 | -7.65% | ― | 21.23% | 36.89% | |
46 Neutral | HK$11.65B | 31.22 | 6.07% | 0.06% | -3.62% | ― |
* Healthcare Sector Average
HK:1302
LifeTech Scientific Corporation
1.55
-0.45
-22.50%
HK:0853
MicroPort Scientific
6.08
-5.94
-49.46%
HK:9996
Peijia Medical Ltd.
3.92
-1.79
-31.35%
HK:1789
AK Medical Holdings Ltd.
4.49
-1.01
-18.41%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-4.67
-78.49%
HK:2172
MicroPort NeuroTech Limited
8.06
-3.68
-31.35%
LifeTech Scientific Corporation Corporate Events
LifeTech’s Bioresorbable Iliac Artery Scaffold Wins NMPA Innovative Device Fast-Track
Oct 20, 2026
LifeTech Scientific has secured admission of its ICS Elpis bioresorbable peripheral balloon-expandable covered scaffold system into China’s Special Examination and Approval Procedure for Innovative Medical Devices. The product, designed for ...
LifeTech’s SureCham Aortic Arch Stent Graft Wins Fast-Track Approval Route in China
Sep 24, 2026
LifeTech Scientific has announced that its jointly developed SureCham Aortic Arch Single-Branch Stent Graft System has been accepted into China’s Special Examination and Approval Procedure for Innovative Medical Devices. The device, created ...
LifeTech Valve System Wins Fast-Track Status in China
Sep 10, 2026
LifeTech Scientific has announced that its Lantval Aortic Valve Replacement System has been admitted into the National Medical Products Administration’s Special Examination and Approval Procedure for Innovative Medical Devices, marking the c...
LifeTech Scientific Swings to Interim Loss on Revenue Decline and FX Hit
Aug 28, 2026
LifeTech Scientific Corporation reported interim revenue of RMB600.8 million for the six months ended 30 June 2026, down 11.2% year on year, with gross profit falling 6.4% to RMB465.9 million as weaker sales and lower cost of sales reshaped its ma...
LifeTech Scientific Flags Interim Loss on Lower Revenue and One-Off Costs
Aug 12, 2026
LifeTech Scientific has warned that its unaudited net profit attributable to shareholders for the six months ended 30 June 2026 is expected to fall sharply to about RMB110 million to RMB120 million, from RMB238.5 million a year earlier, mainly due...
LifeTech Scientific Names New Authorised Representative After Board Change
Aug 12, 2026
LifeTech Scientific Corporation has appointed executive director Fang Yu as an authorised representative of the company under Hong Kong listing rules, effective 12 August 2026. This move follows the previously disclosed resignation of executive di...
LifeTech Scientific Sets August Board Meeting for Interim Results and Dividend Review
Aug 12, 2026
LifeTech Scientific Corporation has scheduled a board meeting for 28 August 2026 to review and approve the unaudited interim results for the six months ended 30 June 2026, and to authorise their publication on the Hong Kong stock exchange and the ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.